

---

## Delanzomib (CEP-18770)

产品编号: D51593

CAS: 847499-27-8

分子式: C<sub>21</sub>H<sub>28</sub>BN<sub>3</sub>O<sub>5</sub>

纯度: ≥98%

InChi: InChI=1S/C<sub>21</sub>H<sub>28</sub>BN<sub>3</sub>O<sub>5</sub>/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H<sub>2</sub>,1-3H<sub>3</sub>, (H,24,28)(H,25,27)/t14-,18+,19+/m1/s1

InChi Key: SJFBTAPEPRWNKH-CCKFTAQKSA-N

Smiles: CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=CC=CC(=N1)C1C=CC=CC=1)[C@@H](C)O)B(O)O

外观: 固体粉末

作用通路: Apoptosis

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations.